Sign In
Buy ABUS
$4.34
-0.0700 (-1.59%)
At Close: Jul 31, 2026
Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update
07:30am, Thursday, 05'th Aug 2021
New data on AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress™ ; all AB-729 abstracts selected for best of ILC�
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
08:00am, Tuesday, 03'rd Aug 2021
WARMINSTER, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commerciali
Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update
08:00am, Thursday, 29'th Jul 2021
WARMINSTER, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commerciali
Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist
09:03am, Thursday, 08'th Jul 2021
Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Inform
Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic hepa
Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity
04:51pm, Tuesday, 06'th Jul 2021
The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ:ABUS).
Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B
10:19am, Tuesday, 06'th Jul 2021
Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-
WARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) today announced that the companies have ente
Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
11:32am, Tuesday, 29'th Jun 2021
Arbutus presented five abstracts at EASL International Liver Congress 2021, one presentation dealing with long-term dosing of AB-729 for Hepatitis B patients was given as a late-breaker oral presentat
ABUS Stock Price Increased Over 15% Pre-Market: Why It Happened
05:05am, Monday, 28'th Jun 2021
The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 15% pre-market. This is why it happened.
AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks
Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June
07:30am, Wednesday, 02'nd Jun 2021
Conference Call and Webcast to discuss the new data being presented at EASL scheduled for 8:00 AM ET, Monday, June 28, 2021
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q1 2021 Results - Earnings Call Transcript
02:07pm, Wednesday, 05'th May 2021
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q1 2021 Results - Earnings Call Transcript
Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update
07:30am, Wednesday, 05'th May 2021
AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (H
Arbutus Biopharma Stocks Is Trading Higher On Pan-Coronavirus Research Pact
10:08am, Thursday, 01'st Apr 2021
Arbutus Biopharma Corp (NASDAQ: ABUS), X-Chem Inc, and Proteros biostructures GmbH have entered into discovery, research, and license agreement focused on discovering novel inhibitors targeting
